Prognostic impact of histology on early-stage non-small cell lung cancer

Chest

Volumn 140, Issue 1, 2011, Pages 135-145

  Maeda, Ryo ^a   Yoshida, Junji ^a   Ishii, Genichiro ^a   Hishida, Tomoyuki ^a   Nishimura, Mitsuyo ^a   Nagai, Kanji ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SMOKING;

EID: 79960394817     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-2391     Document Type: Article

References (30)

1. Yoshida J, Nagai K, Asamura H, et al; Japanese Joint Committee for Lung Cancer Registration. Visceral pleura invasion impact on non-small cell lung cancer patient survival: its implications for the forthcoming TNM staging based on a large-scale nation-wide database. J Thorac Oncol. 2009;4(8): 959-963.
2. Rena O, Papalia E, Ruffini E, et al. Stage I pure bronchioloalveolar carcinoma: recurrences, survival and comparison with adenocarcinoma of the lung. Eur J Cardiothorac Surg. 2003;23(3):409-414. (Pubitemid 36298552)
3. Okada M, Nishio W, Sakamoto T, et al. Evolution of surgical outcomes for nonsmall cell lung cancer: time trends in 1465 consecutive patients undergoing complete resection. Ann Thorac Surg. 2004;77(6):1926-1930, discussion 1931.
4. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122(3):1037-1057.
5. Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer. 2001; 31(2-3):139-148. (Pubitemid 32107010)
6. Sobue T, Yamamoto S, Hara M, Sasazuki S, Sasaki S, Tsugane S; JPHC Study Group. Japanese Public Health Center. Cigarette smoking and subsequent risk of lung cancer by histologic type in middle-aged Japanese men and women:the JPHC study. Int J Cancer. 2002;99(2):245-251. (Pubitemid 34309482)
7. Yun YH, Lim MK, Jung KW, et al. Relative and absolute risks of cigarette smoking on major histologic types of lung cancer in Korean men. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2125-2130. (Pubitemid 41603256)
8. Stellman SD, Resnicow K. Tobacco smoking, cancer and social class. IARC Sci Publ. 1997;138(138):229-250.
9. Margetts BM, Jackson AA. Interactions between people's diet and their smoking habits: the dietary and nutritional survey of British adults. BMJ. 1993;307(6916):1381-1384. (Pubitemid 23341666)
10. Ogle KS, Swanson GM, Woods N, Azzouz F. Cancer and comorbidity: redefining chronic diseases. Cancer. 2000;88(3): 653-663. (Pubitemid 30056943)
11. Meliska CJ, Stunkard ME, Gilbert DG, Jensen RA, Martinko JM. Immune function in cigarette smokers who quit smoking for 31 days. J Allergy Clin Immunol. 1995;95(4): 901-910.
12. Goldstraw P, Crowley J, Chansky K, et al; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706-714. (Pubitemid 47357522)
13. Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
14. Massaro J. Competing risks. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics. New York, NY: John Wiley; 1998:824-835.
15. Holmberg L, Bill-Axelson A, Helgesen F, et al; Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347(11):781-789.
16. Harpole DH Jr, Herndon JE II, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 1995; 55(1):51-56.
17. Tammemagi MC, McLaughlin JR, Mullen JB, et al. A study of smoking, p53 tumor suppressor gene alterations and non-small cell lung cancer. Ann Epidemiol. 2000;10(3): 176-185. (Pubitemid 30171275)
18. Langendijk JA, Thunnissen FB, Lamers RJ, de Jong JM, ten Velde GP, Wouters EF. The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy. Radiother Oncol. 1995;36(3): 218-224.
19. Harpole DH Jr, Herndon JE II, Young WG Jr, Wolfe WG, Sabiston DC Jr. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer. 1995;76(5):787-796.
20. Ichinose Y, Yano T, Asoh H, Yokoyama H, Yoshino I, Katsuda Y. Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer. An analysis in each pathologic stage. J Thorac Cardiovasc Surg. 1995;110(3):601-605.
21. Suzuki K, Nagai K, Yoshida J, et al. Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses. Cancer. 1999;86(10):1976-1984.
22. Ogawa J, Tsurumi T, Yamada S, Koide S, Shohtsu A. Blood vessel invasion and expression of sialyl Lewisx and proliferating cell nuclear antigen in stage I non-small cell lung cancer. Relation to postoperative recurrence. Cancer. 1994; 73(4):1177-1183.
23. Miyoshi K, Moriyama S, Kunitomo T, Nawa S. Prognostic impact of intratumoral vessel invasion in completely resected pathologic stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137(2):429-434.
24. Matsuguma H, Nakahara R, Igarashi S, et al. Pathologic stage I non-small cell lung cancer with high levels of preoperative serum carcinoembryonic antigen: clinicopathologic characteristics and prognosis. J Thorac Cardiovasc Surg. 2008 ;135(1):44-49.
25. Higashiyama M, Kodama K, Yokouchi H, et al. Prognostic value of bronchiolo-alveolar carcinoma component of small lung adenocarcinoma. Ann Thorac Surg. 1999;68(6): 2069-2073. (Pubitemid 30027827)
26. Sakao Y, Miyamoto H, Sakuraba M, et al. Prognostic significance of a histologic subtype in small adenocarcinoma of the lung: the impact of nonbronchioloalveolar carcinoma components. Ann Thorac Surg. 2007;83(1): 209-214. (Pubitemid 44917878)
27. Anami Y, Iijima T, Suzuki K, et al. Bronchioloalveolar carcinoma (lepidic growth) component is a more useful prognostic factor than lymph node metastasis. J Thorac Oncol. 2009;4(8):951-958.
28. Detterbeck FC, Gibson CJ. Turning gray: the natural history of lung cancer over time. J Thorac Oncol. 2008;3(7):781-792.
29. Regnard JF, Santelmo N, Romdhani N, et al. Bronchioloalveolar lung carcinoma: results of surgical treatment and prognostic factors. Chest. 1998;114(1):45-50. (Pubitemid 28337360)
30. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-1500. (Pubitemid 38720929)